Finally, GHSR antagonist attenuated cell proliferation associated with MAPK/ERK and PI3K/AKT signaling in Gefitinib-resistant non-small cell lung cancer cell lines (74). This evidence concerns the gene MAPK1 and non-small cell lung carcinoma.